Machine learning (ML) has accelerated molecular discovery, yet training models to generalize to out-of-distribution (OOD) chemical spaces remains fundamentally constrained by the high cost of experimental validation. In antibiotic discovery, where whole-cell phenotypic high throughput screening (HTS) is resource-intensive, iterative ML-guided compound selection - or Active Learning (AL) - offers a pathway to efficiently navigate available chemical spaces. However, the algorithmic tradeoffs between prioritizing compound novelty (exploration), predicted bioactivity (exploitation), and their impact on OOD generalizability remain unresolved for noisy, whole-cell biological systems. In this work, we systematically evaluate three AL strategies for whole-cell bacterial bioactivity and benchmark their effects on model accuracy, hit rate, and OOD performance. Using retrospective simulations on Mycobacterium tuberculosis HTS data, we identify an optimal AL strategy that balances predicted hit/non-hit novelty with overall hit rate. We then integrate the strategy in a closed-loop Borrelia burgdorferi antibiotic discovery HTS campaign. The AL-guided approach successfully increased the experimental screening hit rate five-fold (from a 0.2% rate within investigator-selected plates to 1.0%). Further, when the trained model was applied in prospective in silico selection of highly diverse compounds across multiple bacterial species, the AL-trained whole-cell inhibition predictor demonstrates 53-fold enrichment over investigator-directed screening (11.0% experimental validation of predicted hits). Of these, 100% demonstrated the intended narrow spectrum activity for Borrelia burgdorferi. These results demonstrate that calibrated AL strategies can overcome data acquisition bottlenecks and train generalizable property predictors able to extrapolate to OOD molecules.
原文链接
分享
引用
